Jonathan P. Foster - 16 Dec 2021 Form 4 Insider Report for Soliton, Inc.

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
17 Dec 2021, 16:07:38 UTC
Prior SEC filing
05 Oct 2021
Next SEC filing
21 Jun 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jonathan P. Foster

Key filing fact

Jonathan P. Foster filed Form 4 for Soliton, Inc. on 17 Dec 2021.

Key facts

  • This page summarizes Jonathan P. Foster's Form 4 filing for Soliton, Inc..
  • 4 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 17 Dec 2021, 16:07.

Change

  • Previous filing in this sequence was filed on 05 Oct 2021.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SOLY transaction Derivative

Stock option (right to buy)

Disposed to Issuer

Transaction value
Shares
-30,000
Change %
-100%
Price
Shares after
0
Date
16 Dec 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
30,000
Exercise price
$1.75
Footnotes
F1
SOLY transaction Derivative

Stock option (right to buy)

Disposed to Issuer

Transaction value
Shares
-15,000
Change %
-100%
Price
Shares after
0
Date
16 Dec 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
15,000
Exercise price
$14.62
Footnotes
F1
SOLY transaction Derivative

Stock option (right to buy)

Disposed to Issuer

Transaction value
Shares
-15,000
Change %
-100%
Price
Shares after
0
Date
16 Dec 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
15,000
Exercise price
$12.94
Footnotes
F1
SOLY transaction Derivative

Warrant (right to buy)

Disposed to Issuer

Transaction value
Shares
-12,500
Change %
-100%
Price
Shares after
0
Date
16 Dec 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
12,500
Exercise price
$1.75
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), immediately prior to the effective time of the merger of Merger Sub with and into the Company (the "Merger"), each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to $22.60 (the "Merger Consideration") minus the exercise price that would be due in cash upon exercise of such option.

Footnote F2

Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .